Q-omics provides the consensus-scored PTMAP1 profile across patient tissues and cancer cell-line models. PTMAP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTMAP1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PTMAP1 RNA expression shows 15,579 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where PTMAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTMAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTMAP1 survival associations across molecular data types. PTMAP1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTMAP1 RNA expression–survival associations across cancer types. High PTMAP1 expression shows unfavorable associations in KIRC and ACC, but favorable associations in HNSC, LUAD, BLCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for PTMAP1 RNA expression.
This table summarizes PTMAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PTMAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTMAP1 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, LUSC, CHOL and STAD. The COAD box plot shows higher PTMAP1 RNA expression in tumor versus normal tissue (log2 FC = +0.994, t-test p < 0.001).
This table shows molecular features associated with PTMAP1 in patient tissues and cancer cell lines. In patient samples, PTMAP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
